Mitoxantrone for paediatric cancer raises toxicity concerns: study
![young child with IV drip in hospital](https://www.ausdoc.com.au/wp-content/uploads/2022/08/ThinkstockPhotos-494379840-1.jpg)
In paediatric cancer patients, mitoxantrone appears to be at least ten times as cardiotoxic as doxorubicin therapy, while daunorubicin therapy may be less so, according to a large cohort study.
“With 5-year survival of childhood cancer now reaching nearly 85%, balancing the potential long-term adverse effects of otherwise effective cancer treatments is an important consideration,” researchers write in JAMA Oncology.